Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in PD-L1 Gene-Altered, Relapsed/Refractory DLBCL
NCT03990961Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Sep 2019
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Chicago. Started Sep 2019; status: terminated.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03990961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990961.